{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:36:16Z","timestamp":1782423376629,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07322-4","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:01:25Z","timestamp":1763413285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world evidence for repurposing hydralazine as a potential epigenetic modulator for psoriasis: a 16-year retrospective nationwide cohort study"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-1079","authenticated-orcid":false,"given":"Shou-En","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6493-1811","authenticated-orcid":false,"given":"Wei\u2011Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7138-7757","authenticated-orcid":false,"given":"Chih-Tsung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-9900","authenticated-orcid":false,"given":"Chi-Hsiang","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-0780","authenticated-orcid":false,"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2902-632X","authenticated-orcid":false,"given":"Bing-Heng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"3","key":"7322_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Educ Chang Am Acad Dermatol. 2017;76(3):377\u201390.","journal-title":"J Educ Chang Am Acad Dermatol"},{"issue":"3","key":"7322_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/HJH.0b013e32835bcce1","volume":"31","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Retailing Hypertens. 2013;31(3):433\u201342; discussion 42-3.","journal-title":"J Retailing Hypertens"},{"issue":"7","key":"7322_CR3","first-page":"718","volume":"21","author":"KS Kommoss","year":"2023","unstructured":"Kommoss KS, Enk A, Heikenw\u00e4lder M, Waisman A, Karbach S, Wild J. Cardiovascular comorbidity in psoriasis - psoriatic inflammation is more than just skin deep. J Dtsch Dermatol Ges. 2023;21(7):718\u201325.","journal-title":"J Dtsch Dermatol Ges"},{"key":"7322_CR4","first-page":"39","volume":"15","author":"ND Brownstone","year":"2021","unstructured":"Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39\u201351.","journal-title":"Biologics"},{"key":"7322_CR5","doi-asserted-by":"publisher","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","volume":"189","author":"R Roskoski Jr","year":"2023","unstructured":"Roskoski R Jr. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023;189:106642.","journal-title":"Pharmacol Res"},{"key":"7322_CR6","doi-asserted-by":"crossref","unstructured":"Olejnik-Wojciechowska J, Boboryko D, Bratborska AW, Rusi\u0144ska K, Ostrowski P, Baranowska M, et al. The role of epigenetic factors in the pathogenesis of psoriasis. 2024;25(7):3831.","DOI":"10.3390\/ijms25073831"},{"key":"7322_CR7","doi-asserted-by":"crossref","unstructured":"Aslani S, Mirarefin SMJ, Zarredar H, Asadi M, Javan MR, Khosrojerdi A, et al. The epigenetic contribution to the pathogenesis of psoriasis: recent advances. 2024.","DOI":"10.2174\/0929867330666230503143824"},{"issue":"11","key":"7322_CR8","doi-asserted-by":"publisher","first-page":"e0142081","DOI":"10.1371\/journal.pone.0142081","volume":"10","author":"JG Krueger","year":"2015","unstructured":"Krueger JG, Su\u00e1rez-Fari\u00f1as M, Cueto I, Khacherian A, Matheson R, Parish LC, et al. A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis. PLoS One. 2015;10(11):e0142081.","journal-title":"PLoS One"},{"key":"7322_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaut.2013.01.001","volume":"41","author":"P Zhang","year":"2013","unstructured":"Zhang P, Zhao M, Liang G, Yin G, Huang D, Su F, et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J Autoimmunity. 2013;41:17\u201324.","journal-title":"J Autoimmunity"},{"key":"7322_CR10","doi-asserted-by":"crossref","unstructured":"Dopytalska K, Ciechanowicz P, Wiszniewski K, Szyma\u0144ska E, Walecka I. The role of epigenetic factors in psoriasis. Int J Mol Sci. 2021;22(17).","DOI":"10.3390\/ijms22179294"},{"issue":"4","key":"7322_CR11","first-page":"376","volume":"73","author":"V Davalos","year":"2023","unstructured":"Davalos V, Esteller M. Cancer epigenetics in clinical practice. CA Cancer J Clin. 2023;73(4):376\u2013424.","journal-title":"CA: A Cancer J For Clinicians"},{"key":"7322_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-4-10","volume":"4","author":"C Arce","year":"2006","unstructured":"Arce C, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Candelaria M, Due\u00f1nas-Gonzalez A. Hydralazine target: from blood vessels to the epigenome. J Transl Med. 2006;4:10.","journal-title":"J Transl Med"},{"issue":"3","key":"7322_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clml.2012.01.005","volume":"12","author":"E Cervera","year":"2012","unstructured":"Cervera E, Candelaria M, L\u00f3pez-Navarro O, Labardini J, Gonzalez-Fierro A, Taja-Chayeb L, et al. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012;12(3):207\u201312.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7322_CR14","first-page":"S540","volume-title":"Preliminary results. Medical oncology (Northwood, London, England)","author":"J Coronel","year":"2011","unstructured":"Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonz\u00e1lez-Fierro A, de la Cruz-Hernandez E, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. In: Preliminary results. Med Oncol. 2011;28 Suppl 1:S540\u20136."},{"issue":"1","key":"7322_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ebiom.2014.11.005","volume":"2","author":"B Tampe","year":"2015","unstructured":"Tampe B, Tampe D, Zeisberg EM, M\u00fcller GA, Bechtel-Walz W, Koziolek M, et al. Induction of Tet3-dependent epigenetic remodeling by low-dose hydralazine attenuates progression of chronic kidney disease. EBioMedicine. 2015;2(1):19\u201336.","journal-title":"EBioMedicine"},{"issue":"4","key":"7322_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/13543784.2017.1291630","volume":"26","author":"JR Espinoza-Zamora","year":"2017","unstructured":"Espinoza-Zamora JR, Labardini-Mendez J, Sosa-Espinoza A, Lopez-Gonzalez C, Vieyra-Garcia M, Candelaria M, et al. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. Expert Opin Investig Drugs. 2017;26(4):481\u201387.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"7322_CR17","first-page":"5","volume":"8","author":"A Schcolnik-Cabrera","year":"2018","unstructured":"Schcolnik-Cabrera A, Dom\u00ednguez-G\u00f3mez G, Due\u00f1as-Gonz\u00e1lez A. Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells. Am J Blood Res. 2018;8(2):5\u201316.","journal-title":"Am J Blood Res"},{"key":"7322_CR18","doi-asserted-by":"crossref","unstructured":"Due\u00f1as-Gonzalez A, Vega MT, Martinez-Ba\u00f1os D, Garc\u00eda-Hidalgo L, Sobrevilla P. Response to hydralazine-valproate in a patient with mycosis fungoides. Case Rep Med. 2010, 2010;657579.","DOI":"10.1155\/2010\/657579"},{"issue":"9","key":"7322_CR19","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","volume":"175","author":"AW Hsing","year":"2015","unstructured":"Hsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan National health insurance research database. JAMA Intern Med. 2015;175(9):1527\u201329.","journal-title":"JAMA Intern Med"},{"key":"7322_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, et al. Taiwan\u2019s National health insurance research database: past and future. Clin Epidemiol. 2019;11:349\u201358.","journal-title":"Clin Epidemiol"},{"issue":"7","key":"7322_CR21","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.jid.2017.01.036","volume":"137","author":"MS Lee","year":"2017","unstructured":"Lee MS, Yeh YC, Chang YT, Lai MS. All-cause and cause-specific mortality in patients with psoriasis in Taiwan: a nationwide population-based study. J Invest Dermatol. 2017;137(7):1468\u201373.","journal-title":"The J Invest Dermatol"},{"issue":"16","key":"7322_CR22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.jacc.2022.08.737","volume":"80","author":"R Mohebi","year":"2022","unstructured":"Mohebi R, Liu Y, Pina IL, Prescott MF, Butler J, Felker GM, et al. Dose-response to Sacubitril\/Valsartan in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2022;80(16):1529\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"7322_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2141.2010.08245.x","volume":"150","author":"FP Santos","year":"2010","unstructured":"Santos FP, Kantarjian H, Fava C, O\u2019Brien S, Garcia-Manero G, Ravandi F, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010;150(3):303\u201312.","journal-title":"Br J Haematol"},{"issue":"5","key":"7322_CR24","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jaad.2018.12.037","volume":"80","author":"A Dhana","year":"2019","unstructured":"Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis. J Educ Chang Am Acad Dermatol. 2019;80(5):1332\u201343.","journal-title":"J Educ Chang Am Acad Dermatol"},{"issue":"3","key":"7322_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","volume":"163","author":"K Abuabara","year":"2010","unstructured":"Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586\u201392.","journal-title":"Br J Dermatol"},{"issue":"4","key":"7322_CR26","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00280-008-0773-z","volume":"63","author":"Y Song","year":"2009","unstructured":"Song Y, Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol. 2009;63(4):605\u201313.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7322_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2867-6-2","volume":"6","author":"A Chavez-Blanco","year":"2006","unstructured":"Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int. 2006;6:2.","journal-title":"Cancer Cell Int"},{"issue":"9","key":"7322_CR28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","volume":"18","author":"M Candelaria","year":"2007","unstructured":"Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18(9):1529\u201338.","journal-title":"Ann Oncol"},{"key":"7322_CR29","doi-asserted-by":"publisher","first-page":"850045","DOI":"10.3389\/fphar.2022.850045","volume":"13","author":"WZ Lin","year":"2022","unstructured":"Lin WZ, Chung CH, Shaiu CY, Yang BH, Chien WC. Hydralazine associated with reduced therapeutic phlebotomy frequency in a nationwide cohort study: real-world effectiveness for drug repurposing. Front Pharmacol. 2022;13:850045.","journal-title":"Front Pharmacol"},{"key":"7322_CR30","volume-title":"Epigenetics and dermatology","author":"Q Lu","year":"2015","unstructured":"Lu Q, Chang C, Richardson BC. Epigenetics and dermatology. Academic; 2015."},{"issue":"1","key":"7322_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/09546634.2018.1473550","volume":"30","author":"JS Mervis","year":"2019","unstructured":"Mervis JS, McGee JS. Epigenetic therapy and dermatologic disease: moving beyond CTCL. J Dermatol Treat. 2019;30(1):68\u201373.","journal-title":"J Dermatological Treat"},{"issue":"5","key":"7322_CR32","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jid.2020.10.012","volume":"141","author":"Y Sawada","year":"2021","unstructured":"Sawada Y, Gallo RL. Role of epigenetics in the regulation of immune functions of the skin. J Invest Dermatol. 2021;141(5):1157\u201366.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"7322_CR33","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247\u201352.","journal-title":"Oncologist"},{"issue":"2","key":"7322_CR34","first-page":"111","volume":"13","author":"RM Trowbridge","year":"2014","unstructured":"Trowbridge RM, Pittelkow MR. Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. J Drugs Dermatol. 2014;13(2):111\u201318.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"7322_CR35","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00438-021-01804-y","volume":"296","author":"Y Luo","year":"2021","unstructured":"Luo Y, Qu K, Kuai L, Ru Y, Huang K, Yan X, et al. Epigenetics in psoriasis: perspective of DNA methylation. Mol Genet Genomics. 2021;296(5):1027\u201340.","journal-title":"Mol Genet Genomics"},{"key":"7322_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13148-016-0297-z","volume":"8","author":"F Zhou","year":"2016","unstructured":"Zhou F, Shen C, Xu J, Gao J, Zheng X, Ko R, et al. Epigenome-wide association data implicates DNA methylation-mediated genetic risk in psoriasis. Clin Epigenet. 2016;8:131.","journal-title":"Clin Epigenet"},{"issue":"4","key":"7322_CR37","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jid.2015.12.029","volume":"136","author":"F Zhou","year":"2016","unstructured":"Zhou F, Wang W, Shen C, Li H, Zuo X, Zheng X, et al. Epigenome-wide association analysis identified nine skin DNA methylation loci for psoriasis. J Invest Dermatol. 2016;136(4):779\u201387.","journal-title":"J Invest Dermatol"},{"issue":"3 Pt 1","key":"7322_CR38","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/jid.2011.348","volume":"132","author":"ED Roberson","year":"2012","unstructured":"Roberson ED, Liu Y, Ryan C, Joyce CE, Duan S, Cao L, et al. A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol. 2012;132(3 Pt 1):583\u201392.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"7322_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.07.011","volume":"60","author":"P Zhang","year":"2010","unstructured":"Zhang P, Su Y, Chen H, Zhao M, Lu Q. Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. J Dermatol Sci. 2010;60(1):40\u201342.","journal-title":"J Dermatological Sci"},{"key":"7322_CR40","doi-asserted-by":"publisher","first-page":"1245876","DOI":"10.3389\/fimmu.2023.1245876","volume":"14","author":"V Natoli","year":"2023","unstructured":"Natoli V, Charras A, Hofmann SR, Northey S, Russ S, Schulze F, et al. DNA methylation patterns in CD4(+) T-cells separate psoriasis patients from healthy controls, and skin psoriasis from psoriatic arthritis. Front Immunol. 2023;14:1245876.","journal-title":"Front Immunol"},{"issue":"2","key":"7322_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jdermsci.2013.07.002","volume":"72","author":"R Hou","year":"2013","unstructured":"Hou R, Yin G, An P, Wang C, Liu R, Yang Y, et al. DNA methylation of dermal MSCs in psoriasis: identification of epigenetically dysregulated genes. J Dermatol Sci. 2013;72(2):103\u201309.","journal-title":"J Dermatological Sci"},{"key":"7322_CR42","doi-asserted-by":"publisher","first-page":"32579","DOI":"10.1038\/srep32579","volume":"6","author":"X Gu","year":"2016","unstructured":"Gu X, Boldrup L, Coates PJ, Fahraeus R, Nylander E, Loizou C, et al. Epigenetic regulation of OAS2 shows disease-specific DNA methylation profiles at individual CpG sites. Sci Rep. 2016;6:32579.","journal-title":"Sci Rep"},{"issue":"12","key":"7322_CR43","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.humpath.2011.02.005","volume":"42","author":"K Ruchusatsawat","year":"2011","unstructured":"Ruchusatsawat K, Wongpiyabovorn J, Protjaroen P, Chaipipat M, Shuangshoti S, Thorner PS, et al. Parakeratosis in skin is associated with loss of inhibitor of differentiation 4 via promoter methylation. Hum Pathol. 2011;42(12):1878\u201387.","journal-title":"Hum Pathol"},{"issue":"7","key":"7322_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/jhg.2015.33","volume":"60","author":"S Yooyongsatit","year":"2015","unstructured":"Yooyongsatit S, Ruchusatsawat K, Noppakun N, Hirankarn N, Mutirangura A, Wongpiyabovorn J. Patterns and functional roles of LINE-1 and Alu methylation in the keratinocyte from patients with psoriasis vulgaris. J Hum Genet. 2015;60(7):349\u201355.","journal-title":"J Hum Genet"},{"issue":"2","key":"7322_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00109-005-0020-6","volume":"84","author":"K Ruchusatsawat","year":"2006","unstructured":"Ruchusatsawat K, Wongpiyabovorn J, Shuangshoti S, Hirankarn N, Mutirangura A. SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J Mol Med (Berl). 2006;84(2):175\u201382.","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"7322_CR46","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jid.2017.11.036","volume":"138","author":"D Verma","year":"2018","unstructured":"Verma D, Ekman AK, Bivik Eding C, Enerb\u00e4ck C. Genome-wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis. J Invest Dermatol. 2018;138(5):1088\u201393.","journal-title":"The J Invest Dermatol"},{"issue":"6343","key":"7322_CR47","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/bmj.285.6343.744-f","volume":"285","author":"P Isaac","year":"1982","unstructured":"Isaac P. Points: hydralazine and psoriasis. Br Med J (Clin Res Ed). 1982;285(6343):744.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6","key":"7322_CR48","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","volume":"36","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797\u2013806.","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"9","key":"7322_CR49","doi-asserted-by":"publisher","first-page":"e19303","DOI":"10.1097\/MD.0000000000019303","volume":"99","author":"X Duan","year":"2020","unstructured":"Duan X, Liu J, Mu Y, Liu T, Chen Y, Yu R, et al. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine (Baltimore). 2020;99(9):e19303.","journal-title":"Med (baltim)"},{"issue":"10","key":"7322_CR50","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1517\/17425255.2014.947263","volume":"10","author":"A Duenas-Gonzalez","year":"2014","unstructured":"Duenas-Gonzalez A, Coronel J, Cetina L, Gonzalez-Fierro A, Chavez-Blanco A, Taja-Chayeb L. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 2014;10(10):1433\u201344.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"7322_CR51","doi-asserted-by":"crossref","unstructured":"Lopes N, Pacheco MB, Soares-Fernandes D, Correia MP, Camilo V, Henrique R, et al. Hydralazine and enzalutamide: synergistic partners against prostate cancer. Biomedicines. 2021;9(8).","DOI":"10.3390\/biomedicines9080976"},{"issue":"3","key":"7322_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","volume":"19","author":"PA Jones","year":"2019","unstructured":"Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Epigenetic therapy in immune-oncology. Nat Rev Cancer. 2019;19(3):151\u201361.","journal-title":"Nat Rev Cancer"},{"key":"7322_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejphar.2016.03.021","volume":"779","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Lin Z, Yin X, Tang L, Luo H, Li H, et al. In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent. Eur J Pharmacol. 2016;779:138\u201346.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"7322_CR54","first-page":"167","volume":"55","author":"S Kumanishi","year":"2019","unstructured":"Kumanishi S, Yamanegi K, Nishiura H, Fujihara Y, Kobayashi K, Nakasho K, et al. Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. Int J Oncol. 2019;55(1):167\u201378.","journal-title":"Int J Oncol"},{"key":"7322_CR55","doi-asserted-by":"crossref","unstructured":"Marina ME, Roman II, Constantin AM, Mihu CM, T\u0103taru AD. VEGF involvement in psoriasis. Clujul Med. 2015;88(3):247\u201352.","DOI":"10.15386\/cjmed-494"},{"issue":"12035","key":"7322_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms222112035","volume":"22","author":"Hyun Ji Lee","year":"2021","unstructured":"Lee HJ, Hong YJ, Kim M. Angiogenesis in chronic inflammatory skin disorders. Int J Mol Sci. 2021;22(21):12035. https:\/\/doi.org\/10.3390\/ijms222112035","journal-title":"International journal of molecular sciences"},{"key":"7322_CR57","doi-asserted-by":"publisher","unstructured":"Daiber A, M\u00fclsch A, Hink U, Mollnau H, Warnholtz A, Oelze M, et al. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol. 2005;96(7B):25i\u201336i. https:\/\/doi.org\/10.1016\/j.amjcard.2005.07.030","DOI":"10.1016\/j.amjcard.2005.07.030"},{"key":"7322_CR58","doi-asserted-by":"publisher","unstructured":"Dobric\u0103 EC, Cozma MA, G\u0103man MA, Voiculescu VM, G\u0103man AM. The involvement of oxidative stress in psoriasis: a systematic review. Antioxidants (Basel). 2022;11(2):282. https:\/\/doi.org\/10.3390\/antiox11020282","DOI":"10.3390\/antiox11020282"},{"key":"7322_CR59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1161\/01.RES.0000134924.89412.70","volume":"95","author":"HJ Knowles","year":"2004","unstructured":"Knowles HJ, Tian YM, Mole DR, Harris AL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res. 2004;95(2):162\u20139. https:\/\/doi.org\/10.1161\/01.RES.0000134924.89412.70","journal-title":"Circ Res"},{"issue":"106689","key":"7322_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2020.106689","volume":"86","author":"WJ Zhu","year":"2020","unstructured":"Zhu WJ, Li P, Wang L, Xu YC. Hypoxia-inducible factor-1: a potential pharmacological target to manage psoriasis. Int Immunopharmacol. 2020;86:106689. https:\/\/doi.org\/10.1016\/j.intimp.2020.106689","journal-title":"Int Immunopharmacol"},{"key":"7322_CR61","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1124\/mol.105.018168","volume":"69","author":"PC Burcham","year":"2006","unstructured":"Burcham PC, Pyke SM. Hydralazine inhibits rapid acrolein-induced protein oligomerization: role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection. Mol Pharmacol. 2006;69(3):1056\u201365. https:\/\/doi.org\/10.1124\/mol.105.018168","journal-title":"Mol Pharmacol"},{"issue":"102729","key":"7322_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2023.102729","volume":"63","author":"A Wro\u0144ski","year":"2023","unstructured":"Wro\u0144ski A, G\u0119gotek A, Skrzydlewska E. Protein adducts with lipid peroxidation products in patients with psoriasis. Redox Biol. 2023;63:102729. https:\/\/doi.org\/10.1016\/j.redox.2023.102729","journal-title":"Redox Biol"},{"issue":"9","key":"7322_CR63","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamadermatol.2013.9957","volume":"150","author":"S Wu","year":"2014","unstructured":"Wu S, Han J, Li WQ, Qureshi AA. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014;150(9):957\u201363. https:\/\/doi.org\/10.1001\/jamadermatol.2013.9957","journal-title":"JAMA Dermatol"},{"key":"7322_CR64","doi-asserted-by":"publisher","unstructured":"Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. 2022;88(3):933\u201341. https:\/\/doi.org\/10.1111\/bcp.15060","DOI":"10.1111\/bcp.15060"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07322-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07322-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07322-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T22:03:55Z","timestamp":1763417035000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07322-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7322"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07322-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study conformed to the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Tri-Service General Hospital (TSGHIRB No.: E202416012). Considering that the Taiwan Longitudinal Generation Tracking Database (LGTD) contains fully anonymized linked information, which does not affect the welfare and right of the subjects, the requirement for informed consent from our participants was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1296"}}